Phibro Animal Health (PAHC) Competitors

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, community ranking, profitability, earnings, risk, analyst recommendations and media sentiment.

Is CALT or PAHC more profitable?

Phibro Animal Health has a net margin of 1.67% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Phibro Animal Health's return on equity of 21.59% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Phibro Animal Health	1.67%	21.59%	5.85%

Does the media prefer CALT or PAHC?

In the previous week, Phibro Animal Health had 1 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 2 mentions for Phibro Animal Health and 1 mentions for Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ)'s average media sentiment score of 1.79 beat Phibro Animal Health's score of 0.03 indicating that Calliditas Therapeutics AB (publ) is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Calliditas Therapeutics AB (publ)	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Phibro Animal Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has better earnings & valuation, CALT or PAHC?

Phibro Animal Health has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	-21.62
Phibro Animal Health	$1.02B	0.93	$2.42M	$0.43	54.40

Do insiders and institutionals have more ownership in CALT or PAHC?

2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Does the MarketBeat Community prefer CALT or PAHC?

Phibro Animal Health received 280 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 59.73% of users gave Phibro Animal Health an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote.

Company	Underperform	Outperform
Calliditas Therapeutics AB (publ)	Outperform Votes 27 55.10%	Underperform Votes 22 44.90%
Phibro Animal Health	Outperform Votes 307 59.73%	Underperform Votes 207 40.27%

Which has more risk & volatility, CALT or PAHC?

Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500.

Do analysts recommend CALT or PAHC?

Calliditas Therapeutics AB (publ) currently has a consensus price target of $39.25, suggesting a potential downside of 1.88%. Phibro Animal Health has a consensus price target of $16.50, suggesting a potential downside of 29.46%. Given Calliditas Therapeutics AB (publ)'s stronger consensus rating and higher probable upside, analysts plainly believe Calliditas Therapeutics AB (publ) is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Phibro Animal Health	3 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.25

Summary

Phibro Animal Health beats Calliditas Therapeutics AB (publ) on 12 of the 17 factors compared between the two stocks.